Atopic dermatitis in adults: observational analysis of 200 patients
DOI:
https://doi.org/10.47196/da.v30i3.2668Keywords:
atopic dermatitis, eczema, atopyAbstract
Background: atopic dermatitis (AD) is a chronic inflammatory dermatosis characterized by xerosis, pruritus and eczema. The diagnosis is clinical, and treatment depends on the severity; mild AD is usually controlled with topical medication while moderate/severe AD usually require systemic treatment. It affects most frequently childhood, so studies in adults are limited.
Objectives: describe the epidemiological, clinical characteristics and treatments in adult outpatients with AD.
Design: a retrospective, observational, descriptive and analytical work was carried out.
Materials and methods: demographic, clinical variables, and different treatments were collected from the medical records of patients with AD between 2019 and 2023. The history and associated factors were compared between the types of severity: mild, moderate, and severe.
Results: of the 200 patients, 62.5% were female. 36% had asthma, and 25.5% had rhinitis. Severely ill patients had a higher frequency of asthma and rhinitis. Methotrexate was used more frequently in moderate and severe disease and 24.7% of patients with severe disease required dupilumab.
Conclusions: in our country, research on adult patients with AD is limited. The severity of the disease is more frequently associated with comorbidities. In mild forms of AD, topical treatments were more used, phototherapy was frequent as an intermediate step between moderate and severe forms, and innovative drugs were predominant in severe forms. It is necessary to continue carrying out higher quality studies that evaluate differences in comorbidities and clinical evolution according to the spectrum of severity.
References
I. Gür Çetinkaya P, Şahiner ÜM. Childhood atopic dermatitis: current developments, treatment approaches, and future expectations. Turk J Med Sci. 2019;8(49):963-984.
II. Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22:125-37.
III. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis. Clinical implications. Allergy Asthma Proc. 2019;1(40):84-92.
IV. Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10:207-215.
V. Paller A, Jaworski JC, Simpson EL, Boguniewicz M, et ál. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19:821-838.
VI. Davis DMR, Drucker AM, Alikhan A, Bercovitch L, et ál. American Academy of Dermatology Guidelines. Awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86:1335-1336.e18.
VII. Futamura M, Leshem YA, Thomas KS, Nankervis H, et ál. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74:288-294.
VIII. Máspero J, Angles MV, Ardusso L, Brancciforte M, et ál. Análisis de una serie de casos de pacientes adultos con dermatitis atópica severa tratados con dupilumab en Argentina. Rev Fac Cien Med Univ Nac Cordoba. 2020;9(77):94-99.
IX. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148:927-940.
X. Gatmaitan JG, Lee JH. Challenges and future trends in atopic dermatitis. Int J Mol Sci. 2023;12(24):11380.
XI. Máspero J, De Paula Motta Rubini N, Zhang J, et ál. Epidemiology of adult patients with atopic dermatitis in AWARE 1: a second international survey. World Allergy Organ J. 2023;16:100724.
XII. Hagenström K, Sauer K, Mohr N, Dettmann M, et ál. Prevalence and medications of atopic dermatitis in Germany: claims data analysis. Clin Epidemiol. 2021;22(13):593-602.
XIII. Herrera-Sánchez DA, Hernández-Ojeda M, Vivas-Rosales IJ. Epidemiological study on atopic dermatitis in Mexico. Rev Alerg Mex. 2019;66:192-204.
XIV. Andersen YMF, Egeberg A, Skov L, Thyssen JP. Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr Dermatol Rep. 2017;6:35-41.
XV. Campanati A, Bianchelli T, Gesuita R, Foti C, et ál. Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study. Arch Dermatol Res. 2022;314:593-603.
XVI. Wollenberg A, Kinberger M, Arents B, Aszodi N, et ál. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36:1409-1431.
XVII. Ardusso L, Castro C, De Gennaro M, Hermida D, et ál. Guías para el Diagnóstico y Tratamiento de la Dermatitis Atópica 2019. Sociedad Argentina de Dermatología-Asociación Argentina de Alergia e Inmunología Clínica 2019. Disponible en: https://alergia.org.ar/pdfs/guias_argentinas_dermatitis_atopica_2019.pdf.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
